APP Function in the Brain: Novel Interactions with Pancortin
About the Research Project
Program
Award Type
Postdoctoral Fellowship
Award Amount
$87,500
Active Dates
July 01, 2009 - September 30, 2011
Grant ID
A2009603
Mentor(s)
Dennis J. Selkoe, MD, Brigham and Women's Hospital
Goals
I aim to address the normal function and signaling pathways surrounding APP in the central nervous system. We have identified Pancortins as putative ligands for APP in the central nervous system, and I aim to determine to what extent Pancortins affect APP cleavage and amyloid beta production.
Summary
Amyloid beta is the toxic agent that attacks neurons in the brains of Alzheimer’s disease sufferers. Amyloid beta is produced by cutting a larger protein called APP. This proposal looks at why our bodies produce APP in the first place. In the past, work from our lab and others showed that APP is necessary for our neurons to be made properly during development. Our lab has just found that other proteins, called Pancortins, affect the function and perhaps the cutting of APP to make amyloid beta. This proposal aims to: 1) examine how Pancortins and APP work together to allow neurons to be made properly in the brain and 2) study how Pancortins affect APP cutting. If these goals are accomplished and researchers better understand how amyloid beta is generated, it will help them design novel and more effective preventative treatments for Alzheimer’s disease.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Identifying Women-Specific and Men-Specific Risk Factors for Alzheimer’s Disease
Active Dates
July 01, 2022 - June 30, 2024
Principal Investigator
Gael Chetelat, PhD
Alzheimer's Disease Research
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD
Mitochondrial Prodrug to Treat Repeated Mild Traumatic Brain Injury
Active Dates
September 08, 2021 - December 31, 2023
Principal Investigator
Patrick Sullivan, PhD